Quest Diagnostics Incorporated
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quest Diagnostics Incorporated
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
The test, which is the first for the condition to win an EUA using actual patient samples, provides results in about three and a half hours.
This year’s annual HLTH meeting drew more than 9,000 people to Las Vegas from 13-16 November and hundreds of exhibitors. In this first part of a two-part roundup, Medtech Insight highlights interviews with C-suite executives at Mirvie, Grail, Biofourmis, Komodo Health and Babson Diagnostics.
Following its decision to maintain a stock listing for SillaJen earlier this month, the Korea Exchange has done the same for Kolon TissueGene, which had faced delisting but has resumed trading amid decisive moves to improve its business.
- Diagnostic Imaging Services
- Other Names / Subsidiaries
- ADI Holding Company
- Athena Diagnostics
- Blueprint Genetics
- Boyce and Bynum Pathology Laboratories
- California Laboratory Associates (CLA)
- Celera Group
- Cleveland HeartLab Inc.
- Hurley Medical Center
- Pathway Diagnostics
- Shiel Medical Laboratory
- Solstas Lab Partners
- Summit Health
- Superior Mobile Medics
- Mid America Clinical Laboratories (MACL)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.